Monjuvi added to Rituxan and Revlimid extended progression-free survival from 14 to 22 months in follicular lymphoma, ...

Objective To evaluate the cost-effectiveness of polatuzumab vedotin–rituximab–cyclophosphamide, doxorubicin and prednisone (pola-R-CHP) in CD20-positive patients with previously untreated diffuse ...

GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma Print details Share Facebook Twitter ...

Dr. Matthew Ku discusses what CAR T-cell therapy is and how it works to target diseases like myelofibrosis.

In this GEN webinar, Dave Lahr, PhD, Senior Director of Bioinformatics at Foghorn Therapeutics, discusses chromatin regulation and epigenetic mechanisms that shape transcriptional responses to ...

Roche’s lymphoma portfolio is one of the broadest in the industry, providing a unique and much-needed opportunity to combine regimens with different and complementary mechanisms of action.

They demonstrated that these LAMM cells specifically impair the therapeutic function of the CAR-T cells against the lymphoma and are therefore contributing to the failure of CAR-T cell therapy.

A research team has discovered a previously unknown mechanism that could explain why many patients with aggressive B-cell lymphoma do not respond to CAR-T cell therapy in the long term. The ...

Furthermore, disease control by maintenance therapy with rituximab every 3 months is used in patients with follicular lymphoma. LON is a common side effect of rituximab treatment.

Late-onset Neutropenia Following Rituximab Therapy Incidence, Clinical Features and Possible Mechanisms Daniel Tesfa; Jan Palmblad Disclosures Expert Rev Hematol. 2011;4 (6):619-625. 0 ...

The FDA approves INCY's Monjuvi in combination with rituximab and lenalidomide for relapsed/refractory follicular lymphoma, its second approved indication.